Intraoperative Imaging of Thoracic Malignancies With Indocyanine Green

Study summary

Our specific aim is to determine if Indocyanine Green (ICG) administered intraoperatively and imaged using our camera will aid in the identification of a suspected lung nodule.

Ask AI to explain this study

Start here

Key things to know

Main goalOther

This describes the study’s primary purpose.

What is being studiedIndocyanine Green

The study team can explain what participation involves.

Who it may be forLung Neoplasms

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 5, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Pennsylvania

Study sponsor

Study overview

What this study is about

Purpose: Other
Study type: Interventional
Phase: Phase 1
Sponsor: University of Pennsylvania
Interventions being studied: Drug: Indocyanine Green

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Adult patients over 18 years of age 2. Patients presenting with a lung nodule or mass presumed to be resectable stage I, II, or IIIa non-small call lung cancer on pre-operative assessment 3. Good operative candidate as determined by a thoracic oncology multidisciplinary team 4. Subject capable of giving informed consent and participating in the process of consent

Reasons someone may not be able to joinExclusion criteria

1. Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery 2. Subjects with a history of iodide allergies 3. At-risk patient populations
Homeless patients
Patients with drug or alcohol dependence
Children and neonates
Patients unable to participate in the consent process

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of PennsylvaniaPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 5, 2018. Always confirm current availability with the study team.

View original record ↗